메뉴 건너뛰기




Volumn 22, Issue SUPPL. 1, 2008, Pages

From Theory to Practice: Applying Current Clinical Knowledge and Treatment Strategies to the Care of Hemophilia A Patients With Inhibitors

Author keywords

Discordant pairs; FEIBA; Hemophilia; Inhibitors; NovoSeven

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; AMINOCAPROIC ACID; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID;

EID: 43449121545     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(08)70001-8     Document Type: Article
Times cited : (19)

References (51)
  • 1
    • 84949470041 scopus 로고    scopus 로고
    • Immune tolerance: high-dose regimen
    • Rodriguez-Merchan E., and Lee C. (Eds), Blackwell Science, Ltd., Oxford, England
    • Brackmann H., and Wallny T. Immune tolerance: high-dose regimen. In: Rodriguez-Merchan E., and Lee C. (Eds). Inhibitors in Patients With Hemophilia (2002), Blackwell Science, Ltd., Oxford, England 45-48
    • (2002) Inhibitors in Patients With Hemophilia , pp. 45-48
    • Brackmann, H.1    Wallny, T.2
  • 2
    • 0031856491 scopus 로고    scopus 로고
    • Factor VIII inhibitors in mild and moderateseverity haemophilia A
    • Hay C. Factor VIII inhibitors in mild and moderateseverity haemophilia A. Haemophilia 4 4 (1998) 558-563
    • (1998) Haemophilia , vol.4 , Issue.4 , pp. 558-563
    • Hay, C.1
  • 3
    • 43449099634 scopus 로고    scopus 로고
    • Kasper CK. Diagnosis and Management of Inhibitors to Factors VIII and IX. An Introductory Discussion for Physicians. Vol No. 34. Montréal, Québec: World Federation of Hemophilia; 2004.
    • Kasper CK. Diagnosis and Management of Inhibitors to Factors VIII and IX. An Introductory Discussion for Physicians. Vol No. 34. Montréal, Québec: World Federation of Hemophilia; 2004.
  • 4
    • 4644334185 scopus 로고    scopus 로고
    • Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction
    • Leissinger C. Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction. Am J Hematol 77 2 (2004) 187-193
    • (2004) Am J Hematol , vol.77 , Issue.2 , pp. 187-193
    • Leissinger, C.1
  • 5
    • 0034107545 scopus 로고    scopus 로고
    • Human coagulation factor FVIIa (recombinant) in the management of limbthreatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency-use rogramme in patients with severe haemophilia or with acquired inhibitors
    • Arkin S., Blei F., Fetten J., and et a. Human coagulation factor FVIIa (recombinant) in the management of limbthreatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency-use rogramme in patients with severe haemophilia or with acquired inhibitors. Blood Coagul Fibrinolysis 11 3 (2000) 255-259
    • (2000) Blood Coagul Fibrinolysis , vol.11 , Issue.3 , pp. 255-259
    • Arkin, S.1    Blei, F.2    Fetten, J.3    et, a.4
  • 6
    • 33846185403 scopus 로고    scopus 로고
    • A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study
    • Astermark J., Donfield S., DiMichele D., and et a. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 109 2 (2007) 546-551
    • (2007) Blood , vol.109 , Issue.2 , pp. 546-551
    • Astermark, J.1    Donfield, S.2    DiMichele, D.3    et, a.4
  • 7
    • 0025180213 scopus 로고
    • Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group
    • Hilgartner M., Aledort L., Andes A., and Gill J. Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group. Transfusion 30 7 (1990) 626-630
    • (1990) Transfusion , vol.30 , Issue.7 , pp. 626-630
    • Hilgartner, M.1    Aledort, L.2    Andes, A.3    Gill, J.4
  • 8
    • 17144437423 scopus 로고    scopus 로고
    • Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors
    • Key N., Aledort L., Beardsley D., and et a. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 80 6 (1998) 912-918
    • (1998) Thromb Haemost , vol.80 , Issue.6 , pp. 912-918
    • Key, N.1    Aledort, L.2    Beardsley, D.3    et, a.4
  • 9
    • 0030837755 scopus 로고    scopus 로고
    • Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors
    • Negrier C., Goudemand J., Sultan Y., Bertrand M., Rothschild C., Lauroua P., and French FEIBA Study Group. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. Thromb Haemost 77 6 (1997) 1113-1119
    • (1997) Thromb Haemost , vol.77 , Issue.6 , pp. 1113-1119
    • Negrier, C.1    Goudemand, J.2    Sultan, Y.3    Bertrand, M.4    Rothschild, C.5    Lauroua, P.6    French FEIBA Study Group7
  • 10
    • 0031743504 scopus 로고    scopus 로고
    • Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery
    • Shapiro A., Gilchrist G., Hoots W., Cooper H., and Gastineau D. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 80 5 (1998) 773-778
    • (1998) Thromb Haemost , vol.80 , Issue.5 , pp. 773-778
    • Shapiro, A.1    Gilchrist, G.2    Hoots, W.3    Cooper, H.4    Gastineau, D.5
  • 11
    • 11044234837 scopus 로고    scopus 로고
    • Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX: the updated Norwegian experience
    • Tjønnfjord G. Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX: the updated Norwegian experience. Haemophilia 10 suppl 2 (2004) 41-45
    • (2004) Haemophilia , vol.10 , Issue.SUPPL. 2 , pp. 41-45
    • Tjønnfjord, G.1
  • 12
    • 0033778140 scopus 로고    scopus 로고
    • Immune tolerance therapy for haemophilia
    • Ho A., Height S., and Smith M. Immune tolerance therapy for haemophilia. Drugs 60 3 (2000) 547-554
    • (2000) Drugs , vol.60 , Issue.3 , pp. 547-554
    • Ho, A.1    Height, S.2    Smith, M.3
  • 13
    • 11044235586 scopus 로고    scopus 로고
    • Inhibitorsin haemophilia: clinical aspects
    • DiMichele D., Rivard G., Hay C., and Antunes S. Inhibitorsin haemophilia: clinical aspects. Haemophilia 10 suppl 4 (2004) 140-145
    • (2004) Haemophilia , vol.10 , Issue.SUPPL. 4 , pp. 140-145
    • DiMichele, D.1    Rivard, G.2    Hay, C.3    Antunes, S.4
  • 14
    • 34248594449 scopus 로고    scopus 로고
    • A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors
    • Teitel J., Berntorp E., Collins P., and et a. A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors. Haemophilia 13 (2007) 256-263
    • (2007) Haemophilia , vol.13 , pp. 256-263
    • Teitel, J.1    Berntorp, E.2    Collins, P.3    et, a.4
  • 15
    • 20144389671 scopus 로고    scopus 로고
    • Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry
    • Parameswaran R., Shapiro A., Gill J., and Kessler C. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 11 2 (2005) 100-106
    • (2005) Haemophilia , vol.11 , Issue.2 , pp. 100-106
    • Parameswaran, R.1    Shapiro, A.2    Gill, J.3    Kessler, C.4
  • 16
    • 43449095901 scopus 로고    scopus 로고
    • Gomperts ED, Astermark J, Gringeri A, Teitel JM. From theory to practice: applying current critical knowledge and treatment strategies to the care of inhibitor patients. Presented at: XXIst Congress of the International Society on Thrombosis and Haemostasis; July 11, 2007; Geneva, Switzerland.
    • Gomperts ED, Astermark J, Gringeri A, Teitel JM. From theory to practice: applying current critical knowledge and treatment strategies to the care of inhibitor patients. Presented at: XXIst Congress of the International Society on Thrombosis and Haemostasis; July 11, 2007; Geneva, Switzerland.
  • 17
    • 0029862923 scopus 로고    scopus 로고
    • Clinical significance of reported changes in pain severity
    • Todd K., Funk K., Funk J., and Bonacci R. Clinical significance of reported changes in pain severity. Ann Emerg Med 27 4 (1996) 485-489
    • (1996) Ann Emerg Med , vol.27 , Issue.4 , pp. 485-489
    • Todd, K.1    Funk, K.2    Funk, J.3    Bonacci, R.4
  • 18
    • 4043121805 scopus 로고    scopus 로고
    • Unresponsiveness to factor VIII inhibitor bypassing agents during haemostatic treatment for life-threatening massive bleeding in a patient with haemophilia A and a high responding inhibitor
    • Hayashi T., Tanaka I., Shima M., and et a. Unresponsiveness to factor VIII inhibitor bypassing agents during haemostatic treatment for life-threatening massive bleeding in a patient with haemophilia A and a high responding inhibitor. Haemophilia 10 4 (2004) 397-400
    • (2004) Haemophilia , vol.10 , Issue.4 , pp. 397-400
    • Hayashi, T.1    Tanaka, I.2    Shima, M.3    et, a.4
  • 19
    • 0033373301 scopus 로고    scopus 로고
    • Prevalence and outcome of intracranial haemorrhage in haemophiliacs - a survey of the paediatric group of the German Society of Thrombosis and Haemostasis (GTH)
    • Klinge J., Auberger K., Auerswald G., Brackmann H., Mauz-Korholz C., and Kreuz W. Prevalence and outcome of intracranial haemorrhage in haemophiliacs - a survey of the paediatric group of the German Society of Thrombosis and Haemostasis (GTH). Eur J Pediatr 158 suppl 3 (1999) S162-S165
    • (1999) Eur J Pediatr , vol.158 , Issue.SUPPL. 3
    • Klinge, J.1    Auberger, K.2    Auerswald, G.3    Brackmann, H.4    Mauz-Korholz, C.5    Kreuz, W.6
  • 20
    • 24644434299 scopus 로고    scopus 로고
    • Intracranialhaemorrhages in French haemophilia patients (1991-2001): clinical presentation, management and prognosis factors for death
    • Stieltjes N., Calvez T., Demiguel V., et al. Intracranialhaemorrhages in French haemophilia patients (1991-2001): clinical presentation, management and prognosis factors for death. Haemophilia 11 5 (2005) 452-458
    • (2005) Haemophilia , vol.11 , Issue.5 , pp. 452-458
    • Stieltjes, N.1    Calvez, T.2    Demiguel, V.3
  • 21
    • 6544275284 scopus 로고    scopus 로고
    • Prevalence and incidence of intracranial haemorrhage in a population of children with haemophilia
    • Nelson Jr. M., Maeder M., Usner D., et al., Hemophilia Growth and Development Study. Prevalence and incidence of intracranial haemorrhage in a population of children with haemophilia. Haemophilia 5 5 (1999) 306-312
    • (1999) Haemophilia , vol.5 , Issue.5 , pp. 306-312
    • Nelson Jr., M.1    Maeder, M.2    Usner, D.3
  • 22
    • 33645995723 scopus 로고    scopus 로고
    • Unresolved issues in diagnosis and management of inherited bleeding disorders in the perinatal period: a White Paper of the Perinatal Task Force of the Medical and Scientific Advisory Council of the National Hemophilia Foundation, USA
    • Kulkarni R., Ponder K., James A., and et a. Unresolved issues in diagnosis and management of inherited bleeding disorders in the perinatal period: a White Paper of the Perinatal Task Force of the Medical and Scientific Advisory Council of the National Hemophilia Foundation, USA. Haemophilia 12 3 (2006) 205-211
    • (2006) Haemophilia , vol.12 , Issue.3 , pp. 205-211
    • Kulkarni, R.1    Ponder, K.2    James, A.3    et, a.4
  • 23
    • 0034902098 scopus 로고    scopus 로고
    • Changes in the occurrence of and risk factors for hemophilia-associated intracranial hemorrhage
    • Nuss R., Soucie J., and Evatt B. Changes in the occurrence of and risk factors for hemophilia-associated intracranial hemorrhage. Am J Hematol 68 1 (2001) 37-42
    • (2001) Am J Hematol , vol.68 , Issue.1 , pp. 37-42
    • Nuss, R.1    Soucie, J.2    Evatt, B.3
  • 24
    • 24644485701 scopus 로고    scopus 로고
    • Iliopsoas haemorrhage in patients with haemophilia: results from one centre
    • Balkan C., Kavakli K., and Karapinar D. Iliopsoas haemorrhage in patients with haemophilia: results from one centre. Haemophilia 11 5 (2005) 463-467
    • (2005) Haemophilia , vol.11 , Issue.5 , pp. 463-467
    • Balkan, C.1    Kavakli, K.2    Karapinar, D.3
  • 25
    • 84949451048 scopus 로고    scopus 로고
    • Pathogenesis of musculoskeletal complications of haemophilia
    • Rodriguez-Merchan E., and Lee C. (Eds), Blackwell Science, Ltd., Oxford, England
    • Rodriguez-Merchan E. Pathogenesis of musculoskeletal complications of haemophilia. In: Rodriguez-Merchan E., and Lee C. (Eds). Inhibitors in Patients With Hemophilia (2002), Blackwell Science, Ltd., Oxford, England 115-119
    • (2002) Inhibitors in Patients With Hemophilia , pp. 115-119
    • Rodriguez-Merchan, E.1
  • 26
    • 33747203480 scopus 로고    scopus 로고
    • Surgical excision of a giant pelvic pseudotumour in a patient with haemophilia A
    • Valentino L., Martinowitz U., Doolas A., and Murali P. Surgical excision of a giant pelvic pseudotumour in a patient with haemophilia A. Haemophilia 12 5 (2006) 541-544
    • (2006) Haemophilia , vol.12 , Issue.5 , pp. 541-544
    • Valentino, L.1    Martinowitz, U.2    Doolas, A.3    Murali, P.4
  • 27
    • 0013297123 scopus 로고    scopus 로고
    • Baxter Healthcare Corporation, Westlake Village, CA
    • FEIBA V. [package insert] (April 2005), Baxter Healthcare Corporation, Westlake Village, CA
    • (2005) [package insert]
    • FEIBA, V.1
  • 29
    • 43449099042 scopus 로고    scopus 로고
    • NovoSeven. European Medicines Agency (EMEA). EPARs for authorised medicinal products for human use. Annex I - Summary of product characteristics. http://www.emea.europa.eu/humandocs/Humans/EPAR/novoseven/novoseven.htm. Updated March 9, 2007. Accessed October 8, 2007.
    • NovoSeven. European Medicines Agency (EMEA). EPARs for authorised medicinal products for human use. Annex I - Summary of product characteristics. http://www.emea.europa.eu/humandocs/Humans/EPAR/novoseven/novoseven.htm. Updated March 9, 2007. Accessed October 8, 2007.
  • 30
    • 4043155658 scopus 로고    scopus 로고
    • Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors
    • Schneiderman J., Nugent D., and Young G. Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors. Haemophilia 10 4 (2004) 347-351
    • (2004) Haemophilia , vol.10 , Issue.4 , pp. 347-351
    • Schneiderman, J.1    Nugent, D.2    Young, G.3
  • 31
    • 34248551364 scopus 로고    scopus 로고
    • Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience
    • Schneiderman J., Rubin E., Nugent D., and Young G. Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience. Haemophilia 13 3 (2007) 244-248
    • (2007) Haemophilia , vol.13 , Issue.3 , pp. 244-248
    • Schneiderman, J.1    Rubin, E.2    Nugent, D.3    Young, G.4
  • 32
    • 13244262642 scopus 로고    scopus 로고
    • Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity
    • Aledort L. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. JThrombHaemost 2 10 (2004) 1700-1708
    • (2004) JThrombHaemost , vol.2 , Issue.10 , pp. 1700-1708
    • Aledort, L.1
  • 33
    • 0348218225 scopus 로고    scopus 로고
    • Immunoadsorption for coagulation factor inhibitors: a retrospective critical appraisal of 10 consecutive cases from a single institution
    • Rivard G., St Louis J., Lacroix S., Champagne M., and Rock G. Immunoadsorption for coagulation factor inhibitors: a retrospective critical appraisal of 10 consecutive cases from a single institution. Haemophilia 9 6 (2003) 711-716
    • (2003) Haemophilia , vol.9 , Issue.6 , pp. 711-716
    • Rivard, G.1    St Louis, J.2    Lacroix, S.3    Champagne, M.4    Rock, G.5
  • 34
    • 0019753424 scopus 로고
    • Current status and trends in the treatment of hemophilic patients with inhibitors
    • Bloom A. Current status and trends in the treatment of hemophilic patients with inhibitors. Prog Clin Biol Res 72 (1981) 123-138
    • (1981) Prog Clin Biol Res , vol.72 , pp. 123-138
    • Bloom, A.1
  • 35
    • 0141921424 scopus 로고    scopus 로고
    • Intracranial haemorrhage among a population of haemophilic patients in Brazil
    • Antunes S., Vicari P., Cavalheiro S., and Bordin J. Intracranial haemorrhage among a population of haemophilic patients in Brazil. Haemophilia 9 5 (2003) 573-577
    • (2003) Haemophilia , vol.9 , Issue.5 , pp. 573-577
    • Antunes, S.1    Vicari, P.2    Cavalheiro, S.3    Bordin, J.4
  • 36
    • 33646002352 scopus 로고    scopus 로고
    • Considerations in the evaluation of haemophilia patients for short-term prophylactic therapy: a paediatric and adult case study
    • Luchtman-Jones L., Valentino L., and Manno C. Considerations in the evaluation of haemophilia patients for short-term prophylactic therapy: a paediatric and adult case study. Haemophilia 12 1 (2006) 82-86
    • (2006) Haemophilia , vol.12 , Issue.1 , pp. 82-86
    • Luchtman-Jones, L.1    Valentino, L.2    Manno, C.3
  • 37
    • 10744231994 scopus 로고    scopus 로고
    • Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay
    • Turecek P., Varadi K., Keil B., and et a. Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay. Pathophysiol Haemost Thromb 33 1 (2003) 16-22
    • (2003) Pathophysiol Haemost Thromb , vol.33 , Issue.1 , pp. 16-22
    • Turecek, P.1    Varadi, K.2    Keil, B.3    et, a.4
  • 39
    • 0031760564 scopus 로고    scopus 로고
    • Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII
    • Hoffman M., Monroe III D., and Roberts H. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis 9 suppl 1 (1998) S61-S65
    • (1998) Blood Coagul Fibrinolysis , vol.9 , Issue.SUPPL. 1
    • Hoffman, M.1    Monroe III, D.2    Roberts, H.3
  • 40
    • 0017785868 scopus 로고
    • Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder [letter]
    • Brackmann H., and Gormsen J. Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder [letter]. Lancet 2 8044 (1977) 933
    • (1977) Lancet , vol.2 , Issue.8044 , pp. 933
    • Brackmann, H.1    Gormsen, J.2
  • 41
    • 33750342991 scopus 로고    scopus 로고
    • A retrospective postlicensure survey of FEIBA efficacy and safety
    • DiMichele D., and Negrier C. A retrospective postlicensure survey of FEIBA efficacy and safety. Haemophilia 12 4 (2006) 352-362
    • (2006) Haemophilia , vol.12 , Issue.4 , pp. 352-362
    • DiMichele, D.1    Negrier, C.2
  • 42
    • 0038441421 scopus 로고    scopus 로고
    • Long-term FEIBA prophylaxis does not prevent progression of existing joint disease
    • Hilgartner M., Makipernaa A., and DiMichele D. Long-term FEIBA prophylaxis does not prevent progression of existing joint disease. Haemophilia 9 3 (2003) 261-268
    • (2003) Haemophilia , vol.9 , Issue.3 , pp. 261-268
    • Hilgartner, M.1    Makipernaa, A.2    DiMichele, D.3
  • 43
    • 34248562674 scopus 로고    scopus 로고
    • Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors
    • Leissinger C., Becton D., Ewing N., and Valentino L. Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors. Haemophilia 13 3 (2007) 249-255
    • (2007) Haemophilia , vol.13 , Issue.3 , pp. 249-255
    • Leissinger, C.1    Becton, D.2    Ewing, N.3    Valentino, L.4
  • 44
    • 0028232368 scopus 로고
    • Pharmacokinetics and pharmacodynamics of recombinant factor VIIa
    • Lindley C., Sawyer W., Macik B., and et a. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 55 6 (1994) 638-648
    • (1994) Clin Pharmacol Ther , vol.55 , Issue.6 , pp. 638-648
    • Lindley, C.1    Sawyer, W.2    Macik, B.3    et, a.4
  • 45
    • 4043184093 scopus 로고    scopus 로고
    • Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A
    • Villar A., Aronis S., Morfini M., and et a. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. Haemophilia 10 4 (2004) 352-359
    • (2004) Haemophilia , vol.10 , Issue.4 , pp. 352-359
    • Villar, A.1    Aronis, S.2    Morfini, M.3    et, a.4
  • 46
    • 3242737794 scopus 로고    scopus 로고
    • Monitoring the bioavailability of FEIBA with a thrombin generation assay
    • Varadi K., Negrier C., Berntorp E., and et a. Monitoring the bioavailability of FEIBA with a thrombin generation assay. JThrombHaemost 1 11 (2003) 2374-2380
    • (2003) JThrombHaemost , vol.1 , Issue.11 , pp. 2374-2380
    • Varadi, K.1    Negrier, C.2    Berntorp, E.3    et, a.4
  • 47
    • 34548096392 scopus 로고    scopus 로고
    • Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors
    • Konkle B., Ebbesen L., Erhardtsen E., and et a. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. JThrombHaemost 5 9 (2007) 1904-1913
    • (2007) JThrombHaemost , vol.5 , Issue.9 , pp. 1904-1913
    • Konkle, B.1    Ebbesen, L.2    Erhardtsen, E.3    et, a.4
  • 48
    • 34548301664 scopus 로고    scopus 로고
    • Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres
    • Morfini M., Auerswald G., Kobelt R., and et a. Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres. Haemophilia 13 5 (2007) 502-507
    • (2007) Haemophilia , vol.13 , Issue.5 , pp. 502-507
    • Morfini, M.1    Auerswald, G.2    Kobelt, R.3    et, a.4
  • 49
    • 30444433618 scopus 로고    scopus 로고
    • Therapeutic decision-making in inhibitor patients
    • Allen G., and Aledort L. Therapeutic decision-making in inhibitor patients. Am J Hematol 81 1 (2006) 71-72
    • (2006) Am J Hematol , vol.81 , Issue.1 , pp. 71-72
    • Allen, G.1    Aledort, L.2
  • 50
    • 0036304070 scopus 로고    scopus 로고
    • Possible synergy between recombinant factor VIIa and prothrombin complex concentrate in hemophilia therapy
    • Key N., Christie B., Henderson N., and Nelsestuen G. Possible synergy between recombinant factor VIIa and prothrombin complex concentrate in hemophilia therapy. Thromb Haemost 88 1 (2002) 60-65
    • (2002) Thromb Haemost , vol.88 , Issue.1 , pp. 60-65
    • Key, N.1    Christie, B.2    Henderson, N.3    Nelsestuen, G.4
  • 51
    • 43449115273 scopus 로고    scopus 로고
    • PRO-FEIBA. A prospective, randomized, cross-over study of an activated prothrombin complex concentrate for secondary prophylaxis in patients with hemophilia A and inhibitors. ClinicalTrials.gov Web site. http://www.clinicaltrial.gov/ct/show/NCT00221195?order=6. Verified September 2005. Accessed August 2, 2006.
    • PRO-FEIBA. A prospective, randomized, cross-over study of an activated prothrombin complex concentrate for secondary prophylaxis in patients with hemophilia A and inhibitors. ClinicalTrials.gov Web site. http://www.clinicaltrial.gov/ct/show/NCT00221195?order=6. Verified September 2005. Accessed August 2, 2006.


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.